| Patents for C07K 14 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof (291,526) |
|---|
| 07/31/2003 | WO2003062446A2 Mrp9 and its use detecting and treating cancer |
| 07/31/2003 | WO2003062431A2 Production of epi-hne-4 comprising reduction of improperly processed form |
| 07/31/2003 | WO2003062426A1 Novel protein, its dna and use thereof |
| 07/31/2003 | WO2003062424A1 Nucleic acid sequence comprising the rna packaging signal of a group 1 coronavirus and the applications thereof |
| 07/31/2003 | WO2003062415A2 Transgenic animal comprising intracellular immunoglobins for xenotransplantation |
| 07/31/2003 | WO2003062411A1 Tyrosine kinase inhibitors |
| 07/31/2003 | WO2003062407A1 INFECTIOUS cDNA CLONES OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS AND EXPRESSION VECTORS THEREOF |
| 07/31/2003 | WO2003062401A2 Compositions and methods for the detection, diagnosis and therapy of hematological malignancies |
| 07/31/2003 | WO2003062400A2 Fiber shaft modifications for efficient targeting |
| 07/31/2003 | WO2003062398A2 NEW TUMOR SUPPRESSOR GENE, p28ING5 |
| 07/31/2003 | WO2003062396A2 Non-endogenous versions of human g protein-coupled receptor: fshr |
| 07/31/2003 | WO2003062395A2 Predictor sets for tyrosine kinase pathways |
| 07/31/2003 | WO2003062393A2 G protein-coupled receptor variants |
| 07/31/2003 | WO2003062391A2 Structural and cytoskeleton-associated proteins |
| 07/31/2003 | WO2003062386A2 Syndecans and angiogenesis |
| 07/31/2003 | WO2003062382A2 Methods to identify evolutionarily significant changes in polynucleotide and polypeptide sequences in domesticated plants and animals |
| 07/31/2003 | WO2003062377A2 COMPLETE GENOME SEQUENCE OF SIVcpzTAN1 |
| 07/31/2003 | WO2003062374A2 Synthetic genes for malarial proteins and methods of use |
| 07/31/2003 | WO2003062370A2 Multimeric proteins and methods of making and using same |
| 07/31/2003 | WO2003062279A1 Nutraceuticals for the treatment, protection and restoration of connective tissues |
| 07/31/2003 | WO2003062277A1 Corticotropin releasing factor receptor 2 agonists |
| 07/31/2003 | WO2003062276A2 Multimers of receptor-binding ligands |
| 07/31/2003 | WO2003062275A1 Glycoisoforms of adiponectin and uses thereof |
| 07/31/2003 | WO2003062274A1 Novel proteins and dnas thereof |
| 07/31/2003 | WO2003062273A2 Modulator of the notch signalling pathway and use thereof in medical treatment |
| 07/31/2003 | WO2003062272A1 Novel strategy for modulating t cell activation which is based on regulating the cd3ε - nck interaction |
| 07/31/2003 | WO2003062271A1 Peptides and nucleic acids of the cathelicidin family, derived from fish, and uses thereof |
| 07/31/2003 | WO2003062270A2 Fluorescent protein from aequorea coerulscens and uses therof |
| 07/31/2003 | WO2003062269A2 Corticotropin releasing factor receptor 2 agonists |
| 07/31/2003 | WO2003062268A2 Corticotropin releasing factor receptor 2 agonists |
| 07/31/2003 | WO2003062262A2 Modulation of heat-shock-protein-based immunotherapies |
| 07/31/2003 | WO2003062212A1 Peptide nucleic acid oligomers from 1-benzenesulfonyl-3-amino acid side chain-4-(2-nucleobase(acetyl))-piperazin-2-ones |
| 07/31/2003 | WO2003061712A1 Diagnostic conjugate useful for intracellular imaging and for differentiating between tumor- and non-tumor cells |
| 07/31/2003 | WO2003061710A1 AGENT CONTROLLING THE APOPTOSIS INDUCTION BY p73 |
| 07/31/2003 | WO2003061697A1 Preventives/remedies for cancer |
| 07/31/2003 | WO2003061681A2 Proteins involved in the regulation of energy homeostasis and organelle metabolism |
| 07/31/2003 | WO2003061680A2 Use of compounds having the biological activity of vasoactive intestinal peptide for the treatment of chronic obstructive pulmonary disease |
| 07/31/2003 | WO2003061603A2 Global suppressors of p53 mutations |
| 07/31/2003 | WO2003061601A2 Aminophospholipid transporter atpase |
| 07/31/2003 | WO2003061590A2 Peptide constructs for treating disease |
| 07/31/2003 | WO2003061589A2 Methods for treating diseases or conditions with peptide constructs |
| 07/31/2003 | WO2003061587A2 USE OF TGF-β ANTAGONISTS TO TREAT OR TO PREVENT CHRONIC TRANSPLANT REJECTION |
| 07/31/2003 | WO2003061583A2 Digenic mutations associated with severe insulin resistance and type 2 diabetes and their use in the diagnosis and treatment of diabetes |
| 07/31/2003 | WO2003061581A2 Compositions and methods for regulating rna stability using polypyrimidine tract proteins |
| 07/31/2003 | WO2003061580A2 Alteration of rab38 function to modulate mammalian pigmentation |
| 07/31/2003 | WO2003061570A2 Engineered binding proteins |
| 07/31/2003 | WO2003061559A2 Binding peptides specific for the extracellular domain of erbb2 and uses therefor |
| 07/31/2003 | WO2003061365A2 A nucleic acid encoding a g-protein-coupled receptor, and uses thereof |
| 07/31/2003 | WO2003046160A3 Methods of increasing protein expression levels |
| 07/31/2003 | WO2003041659A3 Method and identification of downstream mrna ligands to fmrp and their role in fragile x syndrome and associated disorders |
| 07/31/2003 | WO2003035679A3 Molecules |
| 07/31/2003 | WO2003031571A3 Novel human proteins, polynucleotides encoding them and methods of using the same |
| 07/31/2003 | WO2003029484A3 Antimicrobial methods and materials |
| 07/31/2003 | WO2003027246A3 Antagonists |
| 07/31/2003 | WO2003026400A3 METABOTROPIC GLUTAMATE RECEPTOR 4B (mGluR4) DISRUPTIONS, COMPOSITIONS AND METHODS RELATING THERETO |
| 07/31/2003 | WO2003025140A3 Transductin-1 and transductin-2 and applications to hereditary deafness |
| 07/31/2003 | WO2003016486A3 Bio-synthetic photostimulators and methods of use |
| 07/31/2003 | WO2003016333A3 Virus coat protein/receptor chimeras and methods of use |
| 07/31/2003 | WO2003014702A3 Uses of mammalian cytokine; related reagents |
| 07/31/2003 | WO2003011118A3 Human zona pellucida proteins and methods of their use in diagnosing male infertility |
| 07/31/2003 | WO2003008578A3 Reagents and methods for identifying gene targets for treating cancer |
| 07/31/2003 | WO2003006607A3 Inhibition of apoptosis process and improvement of cell performance |
| 07/31/2003 | WO2003006499A3 Survivin interacting protein tpr1 |
| 07/31/2003 | WO2003006495A3 Human papillomavirus e2 transactivation domain/inhibitor co-crystal and x-ray coordinates defining the inhibitor-binding pocket |
| 07/31/2003 | WO2003005958A3 Hypertension associated transcription factors and uses therefor |
| 07/31/2003 | WO2003002736A3 A walk-through technique for in vitro recombination of polynucleotide sequences |
| 07/31/2003 | WO2003001863A3 Novel endothelially expressed dnas and proteins, and their use |
| 07/31/2003 | WO2003000024A3 Uses of dc-sign and dc-signr for inhibiting hepatitis c virus infection |
| 07/31/2003 | WO2002101005A3 A g-protein coupled receptor and uses therefor |
| 07/31/2003 | WO2002098912A3 Guanylate-cyclase c ligand, administered via the airways, for the treatment of respiratory airway problems |
| 07/31/2003 | WO2002097443A3 Method for diagnosing transmissable spongiform encephalopathy |
| 07/31/2003 | WO2002094202B1 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules |
| 07/31/2003 | WO2002090377A3 Peptides that bind to dna and inhibit dna replication, and methods of use |
| 07/31/2003 | WO2002088357A3 84242, 8035, 55304, 52999, and 21999, novel human proteins and methods of use thereof |
| 07/31/2003 | WO2002086123A3 A human g-protein coupled receptor, hgprbmy11, expressed highly in heart and variants thereof |
| 07/31/2003 | WO2002083849A9 Vascular endothelial growth factor 2 |
| 07/31/2003 | WO2002083729A3 Polypeptides derived from amyloid precursor peptide (app) and their uses |
| 07/31/2003 | WO2002070707A3 Novel gpcr-like proteins and nucleic acids encoding same |
| 07/31/2003 | WO2002064627A3 Crystallization of igf-1 |
| 07/31/2003 | WO2002063000A3 Purified and isolated platelet calcium channel nucleic acids and polypeptides and therapeutic and screening methods using same |
| 07/31/2003 | WO2002062836A3 Detection of antibacterial activity in excretory secretory product of adult trichuris suis |
| 07/31/2003 | WO2002060941A3 Fluorescent proteins |
| 07/31/2003 | WO2002060936A3 Vaccine and compositions for the prevention and treatment of neisserial infections |
| 07/31/2003 | WO2002060464A3 Compositions containing an active fraction isolated from hedyotis diffusae and methods of use |
| 07/31/2003 | WO2002059346A3 Constitutively active, hypersensitive, and nonfunctional receptors as novel therapeutic agents |
| 07/31/2003 | WO2002059292A3 Functional balanced-lethal host-vector systems |
| 07/31/2003 | WO2002059148A3 A method for identification, isolation and production of antigens to a specific pathogen |
| 07/31/2003 | WO2002058716A3 Treatment of inflammatory bowel disease using growth factors |
| 07/31/2003 | WO2002052276A9 Protein s functional assay |
| 07/31/2003 | WO2002048362A3 Embryogenesis associated proteins |
| 07/31/2003 | WO2002047730A3 Intracellular delivery of charged therapeutic moieties to nerve cells by means of targeting proteins |
| 07/31/2003 | WO2002046421A3 Methods and compositions for analysis of m3 muscarinic acetylchloine receptors |
| 07/31/2003 | WO2002044386A3 Targeted regulation of gene expression |
| 07/31/2003 | WO2002042458A3 G protein coupled receptors |
| 07/31/2003 | WO2002039885A3 Compositions and methods for the therapy and diagnosis of ovarian cancer |
| 07/31/2003 | WO2002036732A9 Active variants of fgf with improved specificity |
| 07/31/2003 | WO2002029038A3 Novel proteins and nucleic acids encoding same and antibodies directed against these proteins |
| 07/31/2003 | WO2002027005A3 Enhanced transfection system |
| 07/31/2003 | WO2002024909A3 Receptor nucleic acids and polypeptides |
| 07/31/2003 | WO2002024747A3 Polymorphisms in human genes of cardiovascular regulators and their use in diagnostic and therapeutic applications |